Neovasc to Participate in H.C. Wainwright BIOCONNECT Virtual Conference

Rhea-AI Summary

Neovasc announced its participation in the 2022 H.C. Wainwright BIOCONNECT Virtual Conference, taking place from January 10-13, 2022. CEO Fred Colen will present a recorded session available from January 10 at 7:00 am EST on the conference website, archived for 90 days. Neovasc specializes in medical devices for cardiovascular treatments, focusing on minimally invasive technologies. Notable products include the Neovasc Reducer for refractory angina and the Tiara for mitral valve disease, currently in clinical trials across multiple countries.

VANCOUVER and MINNEAPOLIS, Jan. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ,TSX: NVCN) today announced that its management team will be participating in the 2022 H.C. Wainwright BIOCONNECT Virtual Conference to be held January 10-13, 2022.  A recorded presentation by Fred Colen, Neovasc’s Chief Executive Officer, will be available on the conference website starting at 7:00 am EST on Monday, January 10.  The recording will be archived for 90 days.

About Neovasc Inc.

Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. The Company is a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina. Its products include the Neovasc Reducer™, for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel, and Europe. For more information, visit: www.neovasc.com.

Forward-Looking Statement Disclaimer

Certain statements in this news release contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws that may not be based on historical fact. When used herein, the words “expect”, “anticipate”, “estimate”, “may”, “will”, “should”, “intend,” “believe”, and similar expressions, are intended to identify forward-looking statements. Forward-looking statements may involve, but are not limited to, expectations as to the future growth of the Company, the expansion of its product range and the growing cardiovascular marketplace. Forward-looking statements are based on estimates and assumptions made by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that the Company believes are appropriate in the circumstances. Many factors could cause the Company’s actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including those described in the “Risk Factors” section of the Company’s Annual Report on Form 20-F and in the Management’s Discussion and Analysis for the three and nine months ended September 30, 2021 (copies of which may be obtained at  www.sedar.com or www.sec.gov ).  These factors should be considered carefully, and readers should not place undue reliance on the Company’s forward-looking statements. The Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Investors

Mike Cavanaugh

Westwicke/ICR

Phone: +1.617.877.9641

Mike.Cavanaugh@westwicke.com

Media

Sean Leous

Westwicke/ICR

Phone: +1.646.866.4012

Sean.Leous@westwicke.com

FAQ

What is Neovasc's participation in the 2022 H.C. Wainwright BIOCONNECT Virtual Conference?

Neovasc will participate in the 2022 H.C. Wainwright BIOCONNECT Virtual Conference from January 10-13, 2022, featuring a recorded presentation by CEO Fred Colen available starting January 10 at 7:00 am EST.

When can I watch Neovasc's recorded presentation during the H.C. Wainwright conference?

You can watch Neovasc's recorded presentation by CEO Fred Colen starting January 10, 2022, at 7:00 am EST, on the conference website, with the recording archived for 90 days.

What products does Neovasc focus on in the cardiovascular market?

Neovasc focuses on minimally invasive medical devices, including the Neovasc Reducer for refractory angina and the Tiara for transcatheter mitral valve replacement.

Is the Neovasc Reducer available in the United States?

The Neovasc Reducer is not currently commercially available in the United States but has been available in Europe since 2015.

What is the status of Neovasc's Tiara device?

The Tiara device is currently under clinical investigation in the United States, Canada, Israel, and Europe.